WHWK (Whitehawk Therapeutics) Moat Score: 2/10 (As of Jun. 30, 2026)


WHWK Whitehawk Therapeutics Inc WHWK
38 GF Score
Price $4.64
GF Value $0.27
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Whitehawk Therapeutics Moat Score?

Whitehawk Therapeutics WHWK +5.22% 38 Moat Score is 2 as of Jun. 30, 2026. GuruFocus rates WHWK with a GF Score™ of 38/100 and a GF Value™ of $0.27 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,401 Biotechnology companies, Whitehawk Therapeutics ranks better than 58.1% on this metric.

Whitehawk Therapeutics has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Whitehawk Therapeutics has No Moat: Whitehawk Therapeutics is in the early stages of development with no approved products, lacking significant intellectual property or market presence. The biotech industry is highly competitive, and the company has no discernible moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Whitehawk Therapeutics might have No Moat - Very weak/transient advantages.

Whitehawk Therapeutics  (NAS:WHWK) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Whitehawk Therapeutics Moat Score Related Terms

WHWK vs IMUX, TTRX, ALEC: Moat Score Comparison

For the Biotechnology subindustry, Whitehawk Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Whitehawk Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Whitehawk Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Whitehawk Therapeutics's Moat Score falls into.


WHWK
38GF Score
Whitehawk Therapeutics Inc WHWK
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Whitehawk Therapeutics (WHWK) has a Moat Score of 2 as of Jun. 30, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Whitehawk Therapeutics ranks #587 out of 1401 companies in the Biotechnology industry, placing it in the top 41.9%.
Is Whitehawk Therapeutics' Moat Score too high?
Whitehawk Therapeutics' current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Whitehawk Therapeutics' value of 2 is 0% at this industry median. Based on the distribution chart, Whitehawk Therapeutics ranks #587 out of 1401 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Whitehawk Therapeutics has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Whitehawk Therapeutics' Moat Score compare to IMUX and TTRX?
According to the Biotechnology industry distribution chart, Whitehawk Therapeutics ranks #587 out of 1401 companies for Moat Score. This puts Whitehawk Therapeutics in the upper half of its industry. The industry median Moat Score is 2.00. Whitehawk Therapeutics' value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,401 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Whitehawk Therapeutics's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Whitehawk Therapeutics's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Whitehawk Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Whitehawk Therapeutics (WHWK) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.27, compared to a current price of $4.64 — trading 1618.5% above its estimated fair value. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Whitehawk Therapeutics' overall GF Score™ is 38/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Whitehawk Therapeutics (WHWK), the current Moat Score is 2 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Whitehawk Therapeutics (WHWK) Overvalued in 2026?

Based on GuruFocus' analysis, Whitehawk Therapeutics stock appears to be overvalued. The current stock price of $4.64 is trading 1618.5% above its estimated GF Value™ of $0.27. GuruFocus considers Whitehawk Therapeutics to be Significantly Overvalued.

Key valuation signals for WHWK:

  • Moat Score: 2
  • GF Value™: $0.27 vs. price of $4.64 (1618.5% above fair value)
  • GF Score™: 38/100 with 7 warning signs
  • Industry Position: 0% at the Biotechnology median (#587 of 1401)

No single metric tells the full story. See the WHWK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Whitehawk Therapeutics Business Description

Other Exchanges 3350:Germany
Address 2 Headquarters Plaza East Building, 11th Floor, Morristown, New Jersey, NJ, USA, 07960
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.
38GF Score

Get the complete analysis for WHWK

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.64
Price
$0.27
GF Value